Abstract
SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have